UNSPSC 51312206: Azatadine dimaleate

This classification denotes a histamine-1 receptor antagonist with the molecular formula C20H22N2.2C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F3Q391WTX7, chemically known as 5h-benzo(5,6)cyclohepta(1,2-b)pyridine, 6,11-dihydro-11-(1-methyl-4-piperidinylidene)-, (z)-2-butenedioate (1:2), but more generally known as azatadine dimaleate, which bears US NIH Compound Identifier 5281066.

European Medicines Agency schedules azatadine dimaleate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05645MIG. Most nations, for tariff purposes, schedule azatadine dimaleate under HS 29333999. SMILES: CN1CCC(=C2C3NCCCC3CCC4C2CCCC4)CC1.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51312206 Azatadine dimaleate is a Commodity code that nominally identifies a specific antihistamine pharmaceutical product, but recent state and local procurement activity under this code shows substantial mismatch with the product category. The recent solicitations posted do not purchase azatadine dimaleate itself; instead, they procure broader pharmaceutical and over-the-counter product portfolios, naloxone-based overdose-response systems, and pharmacy benefit program infrastructure. State and local issuing bodies applying this code span county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving participating states including Oregon). The code sees use by entities managing public health supply chains, pharmaceutical procurement for government employee and Medicaid populations, and emergency-response pharmaceutical distribution networks.

Geographic activity centers on Florida, Texas, and Minnesota with multistate reach through cooperative purchasing mechanisms. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; the Texas HHS Commission's Request for Information HHS0017013 (issued April 3, 2026) exploring vendor capacity for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization arrangements; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and over-the-counter products to be distributed through authorized wholesalers across participating state and local facilities. The code appears to capture pharmaceutical procurement more broadly rather than azatadine dimaleate specifically, suggesting either misapplication of the code in source systems or consolidation of pharmaceutical purchases under a single commodity identifier.